反常性痤疮/化脓性汗腺炎病情评价标准研究进展

doi:10.35541/cjd.20210236

中华皮肤科杂志 ›› 2024, Vol. 57 ›› Issue (3): 283-286.doi: 10.35541/cjd.20210236

• 综述 • 上一篇

反常性痤疮/化脓性汗腺炎病情评价标准研究进展

马骁¹ 李诚让¹ 王宝玺² 何艳艳¹ 徐浩翔¹

¹中国医学科学院北京协和医学院皮肤病医院皮肤科，南京 210042；²中国医学科学院北京协和医学院整形外科医院皮肤科，北京 100144

收稿日期:2021-03-22 修回日期:2021-12-06 发布日期:2024-03-04
通讯作者: 何艳艳；徐浩翔 E-mail:heyanyan.jsnj@163.com；xbpipi@163.com
作者简介:本文能否在22年元旦前，尽快待刊，可免答辩
基金资助:
国家自然科学基金（82073471、81703148、81472905），中国医学科学院医学与健康科技创新工程项目（2016-I2M-1-003、2021-I2M-1-001）

Severity assessment criteria for acne inversa/hidradenitis suppurativa

Ma Xiao¹, Li Chengrang¹, Wang Baoxi², He Yanyan¹, Xu Haoxiang¹

¹Department of Dermatology, Hospital for Skin Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China; ²Department of Dermatology, Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100144, China

Received:2021-03-22 Revised:2021-12-06 Published:2024-03-04
Contact: He Yanyan；Xu Haoxiang E-mail:heyanyan.jsnj@163.com；xbpipi@163.com
Supported by:
National Natural Science Foundation of China （82073471, 81703148, 81472905）; CAMS Innovation Fund for Medical Sciences （2016-I2M-1-003, 2021-I2M-1-001）

摘要/Abstract

摘要： 【摘要】反常性痤疮/化脓性汗腺炎不同的患者病情差异大，而病情严重程度决定了治疗方案的选择。已有多个具有临床指导意义的病情评价标准，如Hurley分级、Sartorius评分、化脓性汗腺炎严重程度指数等，广泛应用于临床分级与研究中，但部分标准存在疗效评价敏感性低、适用范围有限等问题。本文介绍近几年提出的几种反常性痤疮/化脓性汗腺炎评价标准，以便更好地评估疾病并进行分级治疗。

关键词: 化脓性汗腺炎, 疾病严重程度指数, 严重程度评价标准

Abstract: 【Abstract】 The degree of severity varies greatly among different patients with acne inversa（AI）/hidradenitis suppurativa（HS）, and disease severity usually determines treatment strategies. There have been a number of severity assessment criteria for AI/HS, such as the Hurley grading system, Sartorius score, HS severity index, etc., which have been widely used in clinical classification and research and have shown clinical guiding significance. However, limitations still exist in some criteria, such as low sensitivity for efficacy evaluation, limited application range, etc. This review introduces several severity assessment criteria for AI/HS that have been proposed in recent years, aiming to better evaluate the disease and carry out graded treatment.

Key words: Hidradenitis suppurativa, Severity of illness index, Severity assessment criteria

马骁李诚让王宝玺何艳艳徐浩翔. 反常性痤疮/化脓性汗腺炎病情评价标准研究进展[J]. 中华皮肤科杂志, 2024,57(3):283-286. doi:10.35541/cjd.20210236

Ma Xiao, Li Chengrang, Wang Baoxi, He Yanyan, Xu Haoxiang. Severity assessment criteria for acne inversa/hidradenitis suppurativa[J]. Chinese Journal of Dermatology, 2024, 57(3): 283-286.doi:10.35541/cjd.20210236

参考文献 30

［1］	中国反常性痤疮/化脓性汗腺炎诊疗专家共识制订小组. 中国反常性痤疮/化脓性汗腺炎诊疗专家共识（2021版）［J］. 中华皮肤科杂志, 2021,54（2）:97⁃104. doi: 10.35541/cjd.20200802.
［2］	Kokolakis G, Wolk K, Schneider⁃Burrus S, et al. Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system［J］. Dermatology, 2020,236（5）:421⁃430. doi: 10.1159/000508787.
［3］	Thorlacius L, Cohen AD, Gislason GH, et al. Increased suicide risk in patients with hidradenitis suppurativa［J］. J Invest Dermatol, 2018,138（1）:52⁃57. doi: 10.1016/j.jid.2017.09.008.
［4］	Ingram JR. Refining the hidradenitis suppurativa Hurley staging system for mild, moderate and severe disease［J］. Br J Dermatol, 2019,180（5）:991⁃992. doi: 10.1111/bjd.17769.
［5］	Rondags A, van Straalen KR, van Hasselt JR, et al. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient⁃reported quality of life and objective disease severity assessment［J］. Br J Dermatol, 2019,180（5）:1214⁃1220. doi: 10.1111/bjd.17508.
［6］	Horváth B, Janse IC, Blok JL, et al. Hurley staging refined: a proposal by the Dutch Hidradenitis Suppurativa Expert Group［J］. Acta Derm Venereol, 2017,97（3）:412⁃413. doi: 10.2340/00015555⁃2513.
［7］	Rondags A, Volkering RJ, Turcan I, et al. The refined Hurley patient questionnaire: an accurate self⁃assessment instrument for deriving the correct refined Hurley stage in hidradenitis suppurativa［J］. Acta Derm Venereol, 2019,99（7）:703⁃704. doi: 10.2340/00015555⁃3126.
［8］	Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System （IHS4）, a novel dynamic scoring system to assess HS severity［J］. Br J Dermatol, 2017,177（5）:1401⁃1409. doi: 10. 1111/bjd.15748.
［9］	Caposiena Caro RD, Cannizzaro MV, Botti E, et al. Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations［J］. J Am Acad Dermatol, 2019,80（5）:1314⁃1321. doi: 10.1016/j.jaad.2018.11. 035.
［10］	Zouboulis CC, Hansen H, Caposiena Caro RD, et al. Adalimumab dose intensification in recalcitrant hidradenitis suppurativa/acne inversa［J］. Dermatology, 2020,236（1）:25⁃30. doi: 10.1159/000503606.
［11］	Napolitano M, Mastroeni S, Fusari R, et al. The International Hidradenitis Suppurativa Severity Score System （IHS4） is a valuable tool to assess gender⁃associated differences［J］. Eur J Dermatol, 2020,30（2）:201⁃203. doi: 10.1684/ejd.2020.3743.
［12］	Hessam S, Scholl L, Sand M, et al. A novel severity assessment scoring system for hidradenitis suppurativa［J］. JAMA Dermatol, 2018,154（3）:330⁃335. doi: 10.1001/jamadermatol.2017.5890.
［13］	Nielsen RM, Lindsø Andersen P, Sigsgaard V, et al. Pain perception in patients with hidradenitis suppurativa［J］. Br J Dermatol, 2020,182（1）:166⁃174. doi: 10.1111/bjd.17935.
［14］	Goldfarb N, Ingram JR, Jemec G, et al. Hidradenitis Suppurativa Area and Severity Index （HASI）: a pilot study to develop a novel instrument to measure the physical signs of hidradenitis suppurativa［J］. Br J Dermatol, 2020,182（1）:240⁃242. doi: 10. 1111/bjd.18335.
［15］	Chiricozzi A, Bettoli V, De Pità O, et al. HIDRAdisk: an innovative visual tool to assess the burden of hidradenitis suppurativa［J］. J Eur Acad Dermatol Venereol, 2019,33（1）:e24⁃e26. doi: 10.1111/jdv.15122.
［16］	Peris K, Lo Schiavo A, Fabbrocini G, et al. HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa［J］. J Eur Acad Dermatol Venereol, 2019,33（4）:766⁃773. doi: 10.1111/jdv.15425.
［17］	Marzano AV, Chiricozzi A, Giovanardi G, et al. Creation of a severity index for hidradenitis suppurativa that includes a validated quality⁃of⁃life measure: the HIDRAscore［J］. J Eur Acad Dermatol Venereol, 2020,34（8）:1815⁃1821. doi: 10.1111/jdv.16328.
［18］	Kirby JS, Butt M, King T. Severity and Area Score for Hidradenitis （SASH）: a novel outcome measurement for hidradenitis suppurativa［J］. Br J Dermatol, 2020,182（4）:940⁃948. doi: 10.1111/bjd.18244.
［19］	Goldfarb N, Lowes MA, Butt M, et al. Hidradenitis Suppurativa Area and Severity Index Revised （HASI⁃R）: psychometric property assessment［J］. Br J Dermatol, 2021,184（5）:905⁃912. doi: 10.1111/bjd.19565.
［20］	Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician′s Global Assessment［J］. J Am Acad Dermatol, 2004,51（4）:563⁃569. doi: 10.1016/j.jaad.2004.04.012.
［21］	Kimball AB, Jemec GB, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response （HiSCR） as the clinical endpoint for hidradenitis suppurativa treatment［J］. Br J Dermatol, 2014,171（6）:1434⁃1442. doi: 10.1111/bjd.13270.
［22］	Frew JW, Jiang CS, Singh N, et al. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: a post hoc analysis of PIONEER 1 and 2 individual patient data［J］. J Am Acad Dermatol, 2020,82（5）:1150⁃1157. doi: 10.1016/j.jaad.2019.12.044.
［23］	Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR （Hidradenitis Suppurativa Clinical Response）: a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo⁃controlled portion of a phase 2 adalimumab study［J］. J Eur Acad Dermatol Venereol, 2016,30（6）:989⁃994. doi: 10.1111/jdv.13216.
［24］	Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial［J］. Ann Intern Med, 2012,157（12）:846⁃855. doi: 10.7326/0003⁃4819⁃157⁃12⁃201212180⁃00004.
［25］	Sartorius K, Emtestam L, Jemec GB, et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity［J］. Br J Dermatol, 2009,161（4）:831⁃839. doi: 10. 1111/j.1365⁃2133.2009.09198.x.
［26］	Amano M, Grant A, Kerdel FA. A prospective open⁃label clinical trial of adalimumab for the treatment of hidradenitis suppurativa［J］. Int J Dermatol, 2010,49（8）:950⁃955. doi: 10.1111/j.1365⁃4632.2010.04545.x.
［27］	Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double⁃blind, placebo⁃controlled crossover trial［J］. J Am Acad Dermatol, 2010,62（2）:205⁃217. doi: 10.1016/j.jaad. 2009.06.050.
［28］	Akdogan N, Dogan S, Incel⁃Uysal P, et al. Serum amyloid A and C⁃reactive protein levels and erythrocyte sedimentation rate are important indicators in hidradenitis suppurativa［J］. Arch Dermatol Res, 2020,312（4）:255⁃262. doi: 10.1007/s00403⁃019⁃02014⁃8.
［29］	Hessam S, Sand M, Gambichler T, et al. Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa （HS）［J］. J Am Acad Dermatol, 2015,73（6）:998⁃1005. doi: 10.1016/j.jaad.2015.08.052.
［30］	Wortsman X, Moreno C, Soto R, et al. Ultrasound in⁃depth characterization and staging of hidradenitis suppurativa［J］. Dermatol Surg, 2013,39（12）:1835⁃1842. doi: 10.1111/dsu.12329.

[1]	张悦陶梦李敏姜沛彧刘韵祎刘乙萱潘婼芯许阳. 玫瑰痤疮病情评价标准研究进展[J]. 中华皮肤科杂志, 2024, 57(2): 182-185.
[2]	王雯竹王宝玺何艳艳徐浩翔. 化脓性汗腺炎/反常性痤疮的分型进展[J]. 中华皮肤科杂志, 2023, 56(9): 892-895.
[3]	张帅邵依张守民李振鲁李建国王建波. 结节性硬化症并发反常性痤疮1例的临床表现及基因变异分析[J]. 中华皮肤科杂志, 2023, 0(3): 20230268-e20230268.
[4]	苑辰闫言王宝玺. 反常性痤疮的生物治疗进展[J]. 中华皮肤科杂志, 2023, 56(3): 270-273.
[5]	王倩漆波张丽霞刘伟兰蕴平. SCORTEN和ABCD-10评估Stevens-Johnson综合征/中毒性表皮坏死松解症预后的比较[J]. 中华皮肤科杂志, 2022, 55(7): 566-570.
[6]	黄雅馨何渊民黄书莉熊霞邓永琼. 血清几丁质酶3样蛋白1水平在寻常型天疱疮中的临床意义研究[J]. 中华皮肤科杂志, 2022, 55(6): 523-527.
[7]	申晨陶娟. 特应性皮炎长期控制的评估演变与达标治疗[J]. 中华皮肤科杂志, 2022, 55(5): 442-445.
[8]	付超吴姣娜郎文超高菲牛贵业边培雯高敏虹司晓青辛琳琳. 皮肤镜检查在评估白癜风疾病活动性中的作用[J]. 中华皮肤科杂志, 2022, 55(3): 268-271.
[9]	李文锐贾苇雪张蕴斌林麟李诚让. nicastrin基因沉默的斑马鱼模型构建及其色素异常机制的初步研究[J]. 中华皮肤科杂志, 2021, 54(5): 402-407.
[10]	李文锐张媛媛贾苇雪何艳艳徐浩翔林麟李诚让. 早老蛋白增强子2基因沉默对HaCaT细胞增殖及γ分泌酶表达的影响[J]. 中华皮肤科杂志, 2021, 54(4): 318-324.
[11]	中国反常性痤疮/化脓性汗腺炎诊疗专家共识制订小组. 中国反常性痤疮/化脓性汗腺炎诊疗专家共识（2021版）[J]. 中华皮肤科杂志, 2021, 54(2): 97-104.
[12]	师蓓朱冠男付萌. 肿瘤坏死因子α抑制剂治疗化脓性汗腺炎四例[J]. 中华皮肤科杂志, 2021, 54(10): 901-903.
[13]	张婉璐张媛媛吴英达程萍李文锐徐浩翔王宝玺何艳艳李诚让. NCSTN基因沉默对HaCaT细胞增殖分化的影响[J]. 中华皮肤科杂志, 2020, 53(9): 704-709.
[14]	肖学敏何艳艳徐浩翔王宝玺林立航. nicastrin基因沉默的HaCaT细胞基因表达谱分析[J]. 中华皮肤科杂志, 2020, 53(6): 445-451.
[15]	陈玉迪刘擘宋晓婷赵作涛. 临界温度阈值检测在冷接触性荨麻疹中的临床应用[J]. 中华皮肤科杂志, 2020, 53(5): 352-355.

反常性痤疮/化脓性汗腺炎病情评价标准研究进展

Severity assessment criteria for acne inversa/hidradenitis suppurativa

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

Metrics

本文评价

推荐阅读 10